Selank

1. Quick Facts

Category: Anxiolytic / Nootropic Peptide

Risk Level: Moderate

Research Status: Limited Human Research

Administration: Intranasal or Subcutaneous

Typical Frequency: 1–3 Times Daily

Estimated Half-Life: Short Plasma Half-Life / Longer Neurological Effects

Primary Research Interest: Anxiety Reduction / Stress Resilience / Cognitive Clarity

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and experimental nootropic compounds. Selank is a biologically active peptide capable of influencing neurological signaling pathways involving anxiety regulation, stress response, neurotransmitter activity, and neurochemical balance. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. It has been investigated for potential anxiolytic, stress-modulating, cognitive, and neurochemical effects without producing the degree of sedation commonly associated with many traditional anxiolytic medications.

Research interest in Selank primarily centers around anxiety regulation, stress resilience, emotional stability, cognitive performance, and neurochemical signaling pathways involving GABA, serotonin, dopamine, and neurotrophic factors.

What People Commonly Claim

Anxiety reduction without significant sedation
Improved resilience to stress
Enhanced focus and mental clarity
Improved emotional stability
Better social confidence and reduced nervousness

What the Literature Actually Shows

Selank is a synthetic analogue of the endogenous peptide tuftsin.
Research suggests anxiolytic effects with relatively low sedative activity.
Studies have investigated effects on anxiety, cognition, immune function, and neurotransmitter signaling.
Preclinical research suggests interactions with GABAergic and other neurotransmitter systems.
Human clinical evidence remains limited compared with conventional psychiatric medications.
Long-term safety and efficacy have not been fully characterized.

3. Reconstitution Guide

Intranasal Administration

Vial Size: 10 mg
Dilutant Type: BAC Water or Sterile Saline
Initial Vial Reconstitution: Add 3 mL to the peptide vial
Transfer Instructions: Withdraw the entire vial contents and transfer into a nasal spray bottle
Final Spray Bottle Dilution: Add an additional 11 mL of dilutant for a total final volume of 14 mL
Final Concentration: 0.714 mg/mL
Spray Bottle Type: 30 mL metered spray bottle delivering approximately 0.175 mL per spray

At this concentration:
• 1 spray (0.175 mL) ≈ 0.125 mg (125 mcg)
• 2 sprays total (1 per nostril) = 250 mcg total dose

Subcutaneous Administration

Vial Size: 10 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 2.5 mL
Final Concentration: 4.00 mg/mL

At this concentration:
• 200 mcg = 0.050 mL (5.0 units)
• 1000 mcg = 0.250 mL (25.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

4. Route of Administration

Selank is most commonly administered intranasally. The intranasal route is generally favored in research discussions because it may facilitate direct access to neurological tissues while avoiding gastrointestinal degradation.

Primary Route: Intranasal Administration
Alternative Route: Subcutaneous Injection
Preferred Timing: Morning and early afternoon administration are commonly discussed
Administration Notes: Intranasal administration remains the most extensively discussed and studied route. Subcutaneous administration is considered more experimental.

5. Common Research Protocols

Product Strength: 0.714 mg/mL (Intranasal) or 4.00 mg/mL (Subcutaneous)
Typical Delivered Amount: 125 mcg per nostril (250 mcg total dose) up to three times daily intranasally; 200–1000 mcg daily subcutaneously
Frequency: 1–3 times daily
Cycle Length: Commonly discussed as 2 weeks on / 2 weeks off
Special Notes: Extended continuous use has not been extensively studied. Some researchers prefer periodic breaks to minimize potential neurological adaptation and maintain subjective effectiveness. High doses may be associated with reduced subjective benefits in some anecdotal reports.

6. Mechanism of Action

Selank appears to influence multiple neurochemical systems involved in anxiety regulation, stress adaptation, neurotransmission, and cognitive function.

Preclinical research has investigated interactions with GABAergic pathways and observed changes in expression of genes involved in neurotransmission and neurochemical signaling. The peptide may also influence serotonin, dopamine, and neurotrophic signaling pathways.

Potential downstream effects discussed in the literature include:

Modulation of GABAergic signaling
Anxiolytic activity with relatively low sedation
Stress resilience support
Neurotransmitter regulation
Potential cognitive and attentional support
Possible neurotrophic signaling effects

7. Potential Benefits

Potential anxiety reduction
Improved stress resilience
Enhanced emotional stability
Possible improvements in cognitive clarity
Reduced mental fatigue
Potential focus enhancement without strong stimulation
Low reported sedative burden compared with many traditional anxiolytics

8. Potential Risks / Side Effects

Moderate

Fatigue
Headache
Nasal irritation with intranasal administration
Emotional flattening in anecdotal reports
Brain fog in anecdotal reports
Reduced motivation in anecdotal reports
Potential neurological adaptation with prolonged use
Limited long-term human safety data

9. Half-Life

Selank is generally described as having a relatively short circulating plasma half-life.

However, downstream neurological and neurochemical signaling effects may persist significantly longer than measurable plasma concentrations, which may help explain why subjective effects can outlast the peptide’s presence in circulation.

10. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation

11. Contraindications / Warnings

Use alongside sedative medications
Severe depressive disorders
Pregnancy or breastfeeding
Severe psychiatric disorders
Known hypersensitivity to peptide compounds

12. Further Study

13. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Peer-reviewed neurology journals
Nootropic peptide research literature
Neurotransmitter and GABAergic signaling research

14. Last Reviewed

June 2026